Drugs / AdCLD-CoV19-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05047692 | Sep 2021 → Dec 2022 | COVID-19 | Cellid Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05520970 | Aug → Nov 2022 | COVID-19 | Cellid Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdCLD-CoV19-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05047692 ↗ |
| Modality | Vaccine | “AdCLD-CoV19-1, a COVID-19 Preventive Vaccine in Healthy Volunteers” NCT05047692 ↗ |
| Route | Intramuscular | “as an intramuscular injection.” NCT05047692 ↗ |